Gyre Therapeutics (NASDAQ:GYRE) Hits New 12-Month Low – Here’s Why

Gyre Therapeutics, Inc. (NASDAQ:GYRE) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $6.01 and last traded at $6.04, with a volume of 95332 shares. The stock had previously closed at $6.26.

Wall Street Analyst Weigh In

Several research firms have issued reports on GYRE. Zacks Research downgraded Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Weiss Ratings downgraded Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, Wall Street Zen downgraded Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Price Performance

The firm has a fifty day simple moving average of $7.33 and a 200 day simple moving average of $7.62. The company has a market cap of $586.06 million, a price-to-earnings ratio of -67.10 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%. Analysts expect that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current year.

Insiders Place Their Bets

In other Gyre Therapeutics news, CEO Ying Luo sold 10,136 shares of Gyre Therapeutics stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the sale, the chief executive officer owned 2,565,226 shares in the company, valued at $20,624,417.04. The trade was a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in GYRE. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after acquiring an additional 1,996 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Gyre Therapeutics by 28.6% during the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after acquiring an additional 89,390 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after acquiring an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in Gyre Therapeutics during the 3rd quarter worth about $38,000. 23.99% of the stock is owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.